Marshall Wace
DTIL icon

Marshall Wace’s Precision BioSciences DTIL Stock Holding History

Marshall Wace’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
415,671
+344,756
+486% +$1.59M ﹤0.01% 1711
2025
Q4 		$295K Buy
+70,915
New +$403K ﹤0.01% 2453
2024
Q4 		– Sell
-12,515
Closed -$112K – 2677
2024
Q3 		$112K Buy
+12,515
New +$120K ﹤0.01% 2363
2023
Q4 		– Sell
-13,753
Closed -$140K – 2266
2023
Q3 		$140K Sell
13,753
-7,879
-36% -$121K ﹤0.01% 2016
2023
Q2 		$344K Sell
21,632
-12,351
-36% -$282K ﹤0.01% 2102
2023
Q1 		$765K Buy
33,983
+27
+0.1% +$890 ﹤0.01% 1930
2022
Q4 		$1.21M Sell
33,956
-45,452
-57% -$1.8M ﹤0.01% 2002
2022
Q3 		$3.1M Sell
79,408
-3,289
-4% -$156K 0.01% 1723
2022
Q2 		$3.97M Buy
+82,697
New +$4.85M 0.01% 1521
2021
Q4 		– Sell
-6,004
Closed -$2.08M – 3943
2021
Q3 		$2.08M Buy
+6,004
New +$2.03M 0.01% 1512
2019
Q4 		– Sell
-77
Closed -$19K – 1775
2019
Q3 		$19K Buy
+77
New +$25.1K ﹤0.01% 1600

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Marshall Wace's DTIL Position: Q1 2026 in Review

Marshall Wace increased its Precision BioSciences (DTIL) stake by 486% in Q1 2026, buying an estimated $1.59M and bringing the position to 415,671 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Marshall Wace first reported a position in DTIL in Q3 2019 and has held it in 11 quarters since. The position peaked at $3.97M in Q2 2022. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Marshall Wace held 415,671 shares of Precision BioSciences worth $2.29M as of Q1 2026.
  • Marshall Wace bought 344,756 Precision BioSciences shares in Q1 2026, an estimated $1.59M.
  • Precision BioSciences made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1711 holding.
  • Marshall Wace first reported a position in Precision BioSciences in Q3 2019 and has held it in 11 quarters since.
  • Marshall Wace's Precision BioSciences position peaked at $3.97M in Q2 2022.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.